Letters, Testimony & Comments

February 25, 2013     Marilyn Tavenner, B.S.N., M.H.A. Administrator Centers for Medicare & Medicaid Services...
March 27 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO)...
January 31 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the...
January 31 2014
Re: Revision of USP Medicare Model Guidelines v6.0 for Benefit Years 2015-2017   Dear Members of the Therapeutic Information and...
November 5 2013
    September 6, 2013   BY ELECTRONIC DELIVERY   Marilyn Tavenner Administrator Centers for Medicare...
September 16 2013
September 6, 2013   BY ELECTRONIC DELIVERY   Marilyn Tavenner Administrator Centers for Medicare & Medicaid...
September 16 2013
  March 15, 2013 Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services...
August 16 2013
Joe V. Selby, M.D., M.P.H. Executive Director Patient-Centered Outcomes Research Institute 1701 Pennsylvania Ave. NW Suite 300...
August 2 2013
Louis Jacques, M.D. Director, Coverage and Analysis Group Centers for Medicare and Medicaid Services 7500 Security Boulevard...
August 2 2013
The Biotechnology Industry Organization (BIO) appreciates the opportunity to submit comments on the "Notification of Comment Period...
July 23 2013
Dear Dr. Conway: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on Section 220.6 of the National...
July 3 2013
Re: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective...
June 25 2013
  BIO’s comments on the Centers for Medicare and Medicaid Services’ (CMS) draft 2014 Call Letter, submitted Friday,...
March 1 2013
Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H....
February 21 2013
The Biotechnology Industry Organization (“BIO”) is pleased to submit the following comments in response to “Proposed...
December 21 2012
          The Biotechnology Industry Organization (BIO) is pleased to submit the following...
December 21 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to submit comments on the New and Reconsidered Clinical...
October 4 2012
Re:  Patient-Centered Outcomes Research Institute (PCORI) Draft Methodology Report Dear Dr. Selby: The Biotechnology Industry...
September 14 2012
Re:      Hospital Outpatient Prospective and Ambulatory Surgical Center Payment Systems and Quality Reporting...
September 4 2012
Re:  Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule; Proposed Rule [CMS-1590-P] Dear Acting...
September 4 2012
Dear Mr. Reed: The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the Draft Methodology for...
August 17 2012
Marilyn Tavenner Acting CMS Administrator Centers for Medicare and Medicaid Services     Dear Acting Administrator...
August 14 2012
Re:      Proposed Project: Enrollment and Recertification of Entities in the 340B Drug Pricing Program (OMB No....
May 18 2012
  The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid...
May 17 2012
BIO Public Statement Medicare Evidence Development & Coverage Advisory Committee Meeting Evidentiary Characteristics for Coverage...
May 16 2012
Re:      CMS-2345-P (Proposed Rule, Medicaid Program; Covered Outpatient Drugs) Dear Ms. Tavenner: The...
April 2 2012
RE: Patient-Centered Outcomes Research Institute (PCORI) Draft National Priorities and Research Agenda Dear Dr. Selby:   ...
March 15 2012
Re: Draft 2013 Call Letter Dear Mr. Blum and Mr. Spitalnic: The Biotechnology Industry Organization (BIO) appreciates this...
March 2 2012
BIO Public Statement: National Patient and Stakeholder Dialogue Thank you for the opportunity to present comments on behalf...
February 27 2012
Centers for Medicare & Medicaid Services  Re:  Docket No. CMS-5060-P:  Proposed rule implementing Section 6002 of...
February 17 2012
Re:    Draft Framework for the National Plan to Address Alzheimer's Disease Dear Ms. Glied:     ...
February 8 2012
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the Department of Health and Human Services...
January 31 2012
Re: Request for Comments Regarding Enhancements to the Part C and Part D Plan Ratings The Biotechnology Industry Organization (BIO)...
January 20 2012
Dear Administrator Berwick: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for...
November 23 2011
Thank you for the opportunity to present comments on behalf of the innovative biotechnology industry which is working to prevent, treat,...
October 25 2011
  Re:  Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 30 2011
RE:      Comments on Proposed Definition of PCORI  1.   Does the definition place appropriate...
September 2 2011
RE:     June 29, 2011 Memorandum on Proposed Changes to the Medicare Coverage Gap Discount Program – Low-Volume...
August 1 2011
BIO’s comments addressed maters such as HRSA’s application of the exclusion, operational concerns arising from the proposed...
July 19 2011
Re: Medicare Program; Medicare Shared Saving Program: Accountable Care Organizations; Proposed Rule [CMS-1345-P] Dear Dr. Berwick:...
June 6 2011
Re: Proposed Guidance Regarding Branded Prescription Drug Fee [Notice 2011-9] Dear Mr. Commissioner: The Biotechnology Industry...
April 29 2011
The Biotechnology Industry Organization (BIO) thanks the Institute of Medicine (IOM) for the opportunity to comment on the successes and...
April 28 2011
RE: Medicare Coverage Gap Discount Program Appeals Guidance The Biotechnology Industry Organization (BIO) appreciates this opportunity...
April 22 2011
Re: Comments on Section 6002 of the Affordable Care Act Dear Sir or Madam: BIO appreciates the opportunity to comment on the...
April 7 2011
Re: Draft 2012 Part D Call Letter Dear Administrator Berwick: The Biotechnology Industry Organization (BIO) appreciates this...
March 4 2011
HHS-OS-2010-002: Request for Information Regarding Value-based Insurance Design in Connection with Preventive Care Benefits The...
March 1 2011
RE: Draft Update to Chapter 4 of the Medicare Managed Care Manual Dear Ms. Moon: The Biotechnology Industry Organization (BIO) is...
February 24 2011
Re: Medicare Program; Proposed Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year...
January 11 2011
Re: Parallel Review of Medical Products [FDA-2010-N-0308] Dear Dr. Berwick and Dr. Hamburg: The Biotechnology Industry Organization (...
December 16 2010
Institute of Medicine Essential Health Benefits BIO Comments 1. What is your interpretation of the word “essential” in...
December 6 2010
Re: Medicare Program; Request for Information Regarding Accountable Care Organizations and the Medicare Shared Savings Program [CMS-1345-...
December 3 2010
Re: Comments on Dispute Resolution Dear Ms. Taylor: The Biotechnology Industry Organization (“BIO”) appreciates this...
November 19 2010
Re: Comments on the Civil Monetary Penalties Dear Mr. Lang: The Biotechnology Industry Organization (BIO) appreciates this...
November 19 2010
Re: Docket No. Docket No. FDA-2010-N-0506, Request for Comments on the Food and Drug Administration Fiscal Year 2011-2015 Strategic...
November 1 2010
Re: Docket No. FDA-2010-D-0246: Draft Guidance for Industry on Residual Drug in Transdermal and Related Drug Delivery Systems Dear Sir...
November 1 2010
Re: Docket No. FDA–2010–N–0437, Development and Distribution of Patient Medication Information for Prescription Drugs...
October 29 2010
BIO submitted comments on FDA’s "Development and Distribution of Patient Medication Information for Prescription Drugs."...
October 29 2010
Dear Ms. Maloy, As President and CEO of the Biotechnology Industry Organization (BIO) and on behalf of our more than 1,100...
September 30 2010
Re: Docket No. FDA-2010-D-0283: Draft Guidance for Industry on Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes...
September 23 2010
Re: Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE: Inclusion of TRICARE Retail Pharmacy Program in...
September 23 2010
Re: Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 17 2010
BIO suggests the proposed guidance address dose finding, additive or synergistic efficacy, additive or synergistic safety, drug...
September 7 2010
BIO is pleased that CMS proposes to reimburse all separately payable drugs and biologicals at average sales price (ASP) plus six percent...
August 31 2010
BIO is concerned about problems in CMS methodology that continue to create instability in reimbursement for separately payable drugs and...
August 24 2010
Although BIO recognizes that preventing a significant cut in physician payment rates is largely within Congress' authority, we urge...
August 24 2010
BIO recently submitted written comments to the FDA on the impact of Risk Evaluation and Mitigation Strategies (REMS) on the healthcare...
August 13 2010
BIO encourages ASPE to proceed with caution on the creation of an inventory and raises some methodological and structural considerations.
August 9 2010
BIO is concerned about CMS’ decision to open an NCA on a recently-approved therapy because it could establish a precedent that...
July 30 2010
BIO comments on the Medicare Coverage Gap Discount Program Draft Third Party Administrator Agreement (TPA Agreement) and the Draft Data...
July 16 2010
Re: Medicare Coverage Gap Discount Program Model Manufacturer Agreement – [CMS-4151-NC] RIN 0938-AQ04 Dear Administrator Tavenner...
June 21 2010
BIO supports the coverage gap discount program and believes that it will increase patient access to life-saving and life enhancing...
May 14 2010
Re: Draft 2011 Part D Call Letter Dear Acting Administrator Frizzera: The Biotechnology Industry Organization (BIO) appreciates this...
March 5 2010
Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on...
November 23 2009
BIO Comments to CMS regarding Proposed Rule CMS-1413-P
August 31 2009
BIO Comments to CMS regarding Proposed Rule CMS-1414-P
August 31 2009
BIO is the largest trade organization to serve and represent the biotechnology industry in the United States and around the globe. BIO...
April 13 2009
BIO’s Comments on the Provisional Appointments for the Institute of Medicine Committee on Comparative Effectiveness Research...
April 2 2009
Re: CMS-4138-IFC4 (Medicare Program; Medicare Advantage and Prescription Drug Programs MIPPA Drug Formulary and Protected Classes...
March 17 2009
Re: Request for Comments regarding the July 30, 2008 CMS Posting of Potential National Coverage Decision Topics Dear Dr. Phurrough:...
September 26 2008
Re: CMS-1404-P (Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and CY 2009 Payment Rates;...
September 2 2008
  Re: Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2009;...
August 29 2008
Re: Medicare Program; Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates [CMS-1390-P]...
June 13 2008
BIO's comments to CMS regarding the tracking sheet and prospective data collection requirements
May 9 2008
Re: Medicare Program; Town Hall Meeting of the Medicare Evidence Development and Coverage Advisory Committee (MedCAC)—April 30,...
April 3 2008
Re: Adding Compendia for the Purposes of Making Medicare Coverage Determinations Dear Ms. Tillman: The Biotechnology Industry...
March 14 2008
BIO's testimony before the Advisory Panel on Ambulatory Payment Classifications regarding the policies the CMS has adopted and is...
March 7 2008
Re: Comments on Draft CY 2009 Call Letter Dear Dr. Tudor: The Biotechnology Industry Organization (BIO) appreciates this opportunity to...
January 30 2008
Re: CMS-1392-FC (Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates) Dear...
January 28 2008
Re: CMS–10224 (Agency Information Collection Activities: Proposed Collection; Comment Request; HCPCS Level II Code Modification...
January 10 2008
Re: CMS-2238-P (Medicaid Program; Prescription Drugs) Dear Acting Administrator Weems: The Biotechnology Industry Organization (BIO)...
December 21 2007
BIO's comments on proposed changes to the 2010 HCPCS Level II Modification Process
December 10 2007
Re: Comments on the USP Draft Medicare Model Guidelines Dear Dr. Perfetto: The Biotechnology Industry Organization (BIO) appreciates...
December 6 2007
BIO's comments to AHRQ regarding the Guide to Conducting Comparative Effectiveness Reviews
November 7 2007
BIO's comments regarding the Effectiveness and Off-Label Use of Recombinant Factor VIIa
October 26 2007
BIO's comments on proposed changes to the 2009 HCPCS Level II Modification Process
September 18 2007
BIO's comments on the Medicare Program; Meeting of the Medicare Evidence Development and Coverage Advisory Committee (MedCAC)
September 17 2007
BIO's comments to CMS regarding proposed changes
September 14 2007
Comments on Notice Regarding the 340B Pricing Program; Children's Hospitals
September 7 2007
BIO's comments on
August 31 2007
BIO letter to CMS
July 24 2007
Re: Proposed Decision Memorandum for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N) Dear Dr....
June 13 2007
Dear Acting Administrator Norwalk: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers...
June 13 2007
BIO's presentation to MCAC
May 10 2007
Regarding their letter to Pharmaceutical Manufacturers on the definition of AMP used to calculate 340B ceiling prices.
April 16 2007
BIO letter to Senators Baucus and Grassley
April 11 2007
BIO's Comments.
April 3 2007
Comments regarding purchasing by state and local governments through Federal Supply Schedules.
April 2 2007
Comments on the HRSA Notice
March 13 2007
Comments on the HRSA Notice
March 13 2007
Comments regarding the treatment of prescription drugs under the Medicaid Drug Rebate Program
February 20 2007
BIO's Comments on the Town Hall Meeting
February 6 2007
Survey Finds Private Sector Negotiations Provide Both Savings and Choice, Making Government Interference Unnecessary.
February 1 2007
BIO's testimony before the Advisory Panel on Ambulatory Payment Classification Groups
February 1 2007
Comments to agency's Proposed Rule regarding collection of and access to claims data under Medicare Part D.
December 18 2006
BIO's presentation to MCAC
December 13 2006
BIO's comments
December 8 2006
BIO's comments to CMS including list of recommended journals to be added
November 22 2006
BIO's letter to CMS Acting Administrator Leslie Norwalk
November 16 2006
BIO's Comments
October 31 2006
BIO's Comments to CMS
October 10 2006
BIO's Comments to CMS
October 10 2006
From the Moran Company
October 6 2006
Comments to CMS on the draft.
September 26 2006
Comments to CMS
September 18 2006
BIO's comments regarding the CMS proposed notice on the five-year review of work relative value units (RVUs) and proposed changes to...
August 21 2006
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify before the Advisory Panel on Ambulatory Payment...
August 18 2006
BIO's comments on the CMS' Tracking Sheet regarding the development of a Clinical Research Policy (CRP) as a reconsideration of...
August 9 2006
On August 1, 2006 the Centers for Medicare and Medicaid Services (CMS) released the fiscal year (FY) 2007 hospital inpatient prospective...
August 8 2006
BIO's comments regarding the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; Section 1013: Identification of...
March 1 2006
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify before the Advisory Panel on Ambulatory Payment...
March 1 2006
BIO's Comments on Authoritative Drug Compendia That May Be Used in Determining Medically Accepted Indications of Drugs and...
February 27 2006
BIO's Comments on the Centers for Medicare and Medicaid Servicesí interim final rule regarding exclusion of vendor purchases...
January 20 2006
To United States Pharmacopeia
January 6 2006
BIO's Comments on the Centers for Medicare and Medicaid Services' final rule regarding revisions to payment policies under the...
December 23 2005
BIOís comments on Noridian Admistrative Services draft LCD regarding drugs and their covered diagnosis.
December 14 2005
BIO's comments on the Office of Inspector General's proposed Rule regarding new Safe Harbors for e-prescribing
December 13 2005
42 CFR 414.804 (CMS-10110)
October 14 2005
Dr. Hambrick and members of the APC Advisory Panel, thank you for the opportunity to be here today. Unfortunately, Terry Ghio was unable...
February 23 2005
BIO's comments on the Proposed Bulletin for Good Guidance Practices released by the Office of Management and Budget (OMB).
January 9 2005
BIO's comments on the Centers for Medicare and Medicaid Servicesí final rule regarding revisions to the hospital outpatient...
January 9 2005
As posted on CMS's Web site on December 3, 2004
December 23 2004
Relating to CMS' proposed rule revisions from the Federal Register CMS-1427-P, August 16, 2004
October 8 2004
Federal Register CMS-4068-P, August 3, 2004
October 4 2004
Relating to CMS's proposed rule revisions
September 24 2004
Under the Medicare physician fee schedule.
September 24 2004
Comments to United States Pharmacopeia's draft Medicare Prescription Drug Benefit Model Guidelines
September 17 2004
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify about the hospital outpatient department...
September 2 2004
Good morning, my name is Jayson Slotnik and I am here on behalf of the Biotechnology Industry Organization (BIO), the trade association...
August 27 2004
Executive Summary The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent...
May 10 2001
June 11 2014
  June 10, 2014   Jacob J. Lew Secretary, Department of the Treasury 1500 Pennsylvania Avenue, NW Washington, D.C. 20220                               Thomas E. Perez Secretary, Department of Labor Frances Perkins Building, 200 Constitution Ave., NW, Washington, DC 20210   Sylvia Mathews Burwell Secretary, Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201   Re: Request for Information Regarding Provider Nondiscrimination   Dear Secretaries Lew, Perez, and Burwell:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the “Request for Information Regarding Provider Nondiscrimination” (the “RFI”) issued by the Departments of Treasury, Labor, and Health and Human Services (“the Departments”) on March 12, 2014.[1]   BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1] 79 Fed. Reg. 14,052 (March 12, 2014).  
May 30 2014
April 10, 2014   BY ELECTRONIC DELIVERY   Marilyn B. Tavenner Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, DC 20201   Re: Patient Protection and Affordable Care Act; Exchange and Insurance Market Standards for 2015 and Beyond; Proposed Rule (CMS-9949-P)   Dear Administrator Tavenner:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the proposed rule issued by the Centers for Medicare & Medicaid Services (CMS) on March 21, 2014, entitled “Exchange and Insurance Market Standards for 2015 and Beyond” (the “Proposed Rule”).[1]   BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.[2] [1] 79 Fed. Reg. 15,808 (March 21, 2014). [2] See, e.g., Congressional Budget Office, Offsetting Effects of Prescription Drug Use on Medicare’s Spending for Medical Services (Nov. 2012), available at: http://www.cbo.gov/sites/default/files/cbofiles/attachments/43741-MedicalOffsets-11-29-12.pdf.   
March 28 2014
March 15, 2013   Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201   Re: Affordable Exchanges Guidance: Letter to Issuers on Federally-facilitated and State Partnership Exchanges   Dear Ms. Tavenner:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft Letter related to the Patient Protection and Affordable Care Act’s (PPACA) health insurance Exchanges that the Centers for Medicare & Medicaid Services (CMS) issued on March 1, 2013, entitled “Letter to Issuers on Federally-facilitated and State Partnership Exchanges” (the “Letter”).1 BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first case. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations and surgical interventions.
March 27 2014
February 25, 2013     Marilyn Tavenner, B.S.N., M.H.A. Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201   Re: Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces   Dear Ms. Tavenner:             The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft letter related to the Patient Protection and Affordable Care Act’s (ACA) health insurance Marketplaces that the Centers for Medicare & Medicaid Services (CMS) issued on February 4, 2014, entitled “Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces” (the “Draft Letter”).[1]             BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1] Center for Consumer Information and Insurance Oversight (CCIIO), Centers for Medicare & Medicaid Services (CMS), Draft 2015 Letter to Issuers in the Federally-facilitated Marketplaces (FFM) (Feb. 4, 2014). Available at: http://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/draft-issuer-letter-2-4-2014.pdf (hereinafter “Draft Letter to Issuers”).   
March 27 2014
VIA ELECTRONIC SUBMISSION   March 1, 2014     Patrick Conway, M.D. Deputy Administrator for Innovation and Quality Chief Medical Officer Centers for Medicare & Medicaid Services Center for Medicare and Medicaid Innovation 7500 Security Boulevard Baltimore, MD 21244   RE: Request for Information: Evolution of ACO Initiatives at CMS   Dear Dr. Conway:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments regarding the Request for Information (RFI) on the “Evolution of ACO Initiatives at CMS” released by the Center for Medicare and Medicaid Innovation (CMMI) on December 20, 2013.[1]  BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.  BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.  In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1]           Center for Medicare and Medicaid Innovation, Request for Information: Evolution of ACO Initiatives at CMS (Dec. 20, 2013), available at: http://innovation.cms.gov/Files/x/Pioneer-RFI.pdf.   
May 29 2014
Many participating hospitals appear to be deviating from the program’s original intent by leveraging 340B discounts for financial gain, rather than improving patient access
March 11 2014
BIO commended the Centers for Medicare & Medicaid Services (CMS) for announcing their decision to halt movement on several proposals in their Medicare Part D draft rule.
March 6 2012
BIO applauded the House Energy and Commerce Committee’s passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law.
April 19 2011
Democratic and Republican party leaders and strategists will share their differing perspectives in a keynote panel, titled "The Future of Healthcare Reform," during a Keynote Luncheon at the 2011 BIO International Convention.
February 9 2011
BIO announces that former Senator John B. Breaux (D-LA), former Member, Senate Finance Committee, along with former Congressman Jim McCrery III (R-LA), former Ranking Member, House Ways & Means Committee, will be panelists at the 13th Annual BIO CEO & Investor Conference.